Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 13, 2026
Headquarters: Melbourne, Victoria, Australia
This filing serves to incorporate a Corporate Presentation (Exhibit 99.1) by reference into the company's active Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document does not contain a financial statement summary within the cover page text.
Material Changes
No material changes to financial performance or operations are detailed in the provided text. The filing is procedural, intended to update registration statements with a corporate presentation.
Guidance, Outlook, and Risks
Management Commentary: The filing references a "Corporate Presentation" (Exhibit 99.1) which likely contains management commentary, outlook, and risk factors, but the content of that presentation is not included in the provided text.
Risks and Contingencies: No specific risks or contingencies are listed in the cover page text.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for detailed financial data, clinical trial updates, and strategic outlook.
- Verify the status of the referenced Registration Statements (Form S-8 and Form F-3) to understand current capital raising capabilities.
- Confirm the company's "development stage" status and its implications for revenue recognition and cash burn rates.